Copyright
©The Author(s) 2019.
World J Clin Cases. May 26, 2019; 7(10): 1221-1229
Published online May 26, 2019. doi: 10.12998/wjcc.v7.i10.1221
Published online May 26, 2019. doi: 10.12998/wjcc.v7.i10.1221
Figure 3 HE staining of specimens from two biopsies (baseline and re-biopsy before osimertinib).
Squamous cell carcinoma was diagnosed by both pathological tests.
- Citation: Zhang Y, Chen HM, Liu YM, Peng F, Yu M, Wang WY, Xu H, Wang YS, Lu Y. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report. World J Clin Cases 2019; 7(10): 1221-1229
- URL: https://www.wjgnet.com/2307-8960/full/v7/i10/1221.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v7.i10.1221